Research and Markets: Basic Platform Report: Leukemia Therapeutics.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c8363) has announced the addition of Basic Platform Report: Leukemia Therapeutics to their offering This "Basic Platform Report: Leukemia Therapeutics " provides a complete and systematic description of the current R&D activities of already established as well as new innovative therapies for the treatment of leukemia (ALL CLL CLL abbr. chronic lymphocytic leukemia CLL, n.pr See leukemia, chronic lymphocytic. CLL 1. Chronic lymphocytic leukemia 2. Cholesterol-lowering lipid , AML AML - A Manufacturing Language and CML 1. CML - A query language. ["Towards a Knowledge Description Language", A. Borgida et al, in On Knowledge Base Management Systems, J. Mylopoulos et al eds, Springer 1986]. 2. CML - Concurrent ML. ). In this informative report, we include extensive presentations of more than 60 of the most important companies active in this field. Our focus has been to review the R&D activities and partnerships in different therapeutic strategies. Hundreds of pipeline drugs and a majority of B2B (Business to Business) Refers to one business communicating with or selling to another. See B2B e-commerce, B2C and B2G. B2B - business to business collaboration and industry-academic alliances are included. Each company profile contains contact data, a short description of the company, partnership activities, pipeline activities, patents and description of products already at market. With the help of the company index of more than 60 firms collaborations can easily be track down any player in the field identified. The "Basic Platform Report: Leukemia Therapeutics" is an excellent source of information that provides you with a solid presentation of this exciting and rapidly evolving field.In each company profile the data is divided according to several different sections and subsections:- General information - Collaborations and alliances - Drug development pipeline (drug name, indications, developmental stages, effects of drugs, mechanism of actions, targets, - combinatory treatments, general comments) - Related patents Some of the drugs included in the report:AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC PKC Protein Kinase C (biochemistry) PKC Public Key Cryptography PKC Public Key Certificate PKC PaKua Chang (Chinese martial art) PKC Paroxysmal Kinesigenic Choreoathetosis 412, PTK PTK Phi Theta Kappa PTK Protein Tyrosine Kinase (insulin receptor) PTK Polskiego Towarzystwa Kardiologicznego (Polish Cardiac Society) PTK Phototherapeutic Keratectomy PTK Pairwise Transient Key 787, Revlimid, Rituxan, SU5416, SCH SCH School SCH Schedule SCH Search SCH Semester Credit Hours SCH Santander Central Hispano (bank in Spain) SCH Socket Head SCH Synchronization Channel SCH Succinylcholine SCH Space Center Houston 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999 For more information visit http://www.researchandmarkets.com/reports/c8363 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion